CSI Market
Sign In | Register

Propanc Biopharma Inc (PPCH) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PPCH Annual Cash Flow →
From Propanc Biopharma Inc through Mar 31 2025, changes in Mar 31 2026's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
9 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-14.29
Depreciation & amortization0.00
Amortization of Other Assets0.20
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation8.01
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction-0.89
Amortization Of Prepaid Shares Issued For Services-
Increase In Gst Receivable-
Write Off Of Deferred Debt Issuance Cost-
Write Off Escrow Account-
Common Stock Issued For Services And Voluntary Ratchet-
Loss From Change In Warrant Derivative Liability-
Issuance Of Preferred Stock For Services-
Loss On Settlement-
Settlement Fees Paid In Form Of Debt-
Derivative Gain Loss On Derivative Net-0.05
Issuance Of Convertible Promissory Notes For Services-
Debt Instrument Decrease Forgiveness-
Gain Loss Related To Litigation Settlement-
Gain From Settlement Of Debt Net-
Allowance On Refundable Advance Deposit-
Common Stock Issuable For Services3.57
Derivative Expense-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-0.28
Increase (Decrease) in Accounts Payable-0.34
Increase (Decrease) in Interest Payable, Net0.03
Increase (Decrease) in Security Deposits0.00
Increase (Decrease) in Prepaid Expense-0.07
Other Working Capital-0.03
Other Noncash Expense0.01
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.04
Discontinued operations0.00
Net Cash flow from Operating Activities-4.08
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payment For Security Deposit-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.08
Other borrowing transactions0.00
Long-term debt - borrowings-0.49
Long-term debt - repayments-0.37
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock4.31
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.95
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Changes In Subscriptions Receivable Related Party-
Related Party Expenses Paid On Behalf Of Company-
Investor Advances-
Loan Proceeds From Principal Stockholder-
Bank Overdraft Liability-
Bank Overdraft-
Collection Of Subscription Receivable-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities4.47
Effect of exchange rate on cash flow0.04
Discontinued operations0.00
Free Cash Flow-4.09
Total Cash Flow0.43
4 historic quarters locked

Sign in to unlock the full Propanc Biopharma Inc cash flow history.

Sign In Create Free Account

About Propanc Biopharma Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260331)
  • Filed with the SEC: May 14, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-023210

Figures are derived from filed reports and may be restated. Historical data is subject to revision.